Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Article Details

Authors
Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

Article Type
Review

DOI
10.7573/dic.212562

Related Articles

Article Page

Abstract

Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for impaired glycemic control and new-onset diabetes mellitus, a condition well established as an important risk factor for cardiovascular disease. On the other hand, some other lipidlowering agents have been shown to have a beneficial effect on glucose metabolism. Profound knowledge of these differences would enable the clinician to choose the right lipid-lowering medication for each individual patient, so that the benefits would outweigh the risk of side effects. This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

Keywords: cardiovascular risk, diabetes mellitus, glycemic control, lipid-lowering.

Citation: Kosmas CE, Silverio D, Sourlas A, Garcia F, Montan PD, Guzman E. Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. Drugs in Context 2018; 7: 212562. DOI: 10.7573/dic.212562

Contributions: Conceived the concepts: CEK; analyzed the data: CEK; wrote the first draft of the manuscript: DS and CEK; contributed to the writing of the manuscript: AS, FG, PDM, EG; agreed with manuscript results and conclusions: CEK, DS, AS, FG, PDM, EG; jointly developed the structure and arguments for the paper: CEK; made critical revisions and approved final version: CEK; all authors reviewed and approved the final manuscript.

Disclosure and potential conflicts of interest: Constantine E Kosmas and Eliscer Guzman are members of the Dyslipidemia Speaker Bureau of Amgen, Inc. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/11/dic.212562-COI.pdf

Acknowledgments: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2018 Kosmas CE, Silverio D, Sourlas A, Garcia F, Montan PD, Guzman E. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Kosmas CE, Silverio D, Sourlas A, Garcia F, Montan PD, Guzman E. https://doi.org/10.7573/dic.212562. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/impact-lipid-lowering-therapy-on-glycemic-control-risk-new-onset-diabetes

Correspondence: Constantine E. Kosmas, MD, PhD, 168-24 Powells Cove Blvd., Beechhurst, NY 11357, USA. cekosmas1@gmail.com

Provenance: invited; externally peer reviewed.

Submitted: 24 September 2018; Peer review comments to author: 2 November 2018; Revised manuscript received: 4 November 2018; Accepted: 6 November 2018; Publication date: 28 November 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF